Compare Skybiotech Healt with Similar Stocks
Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at -1.44% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
Flat results in Dec 25
Risky - Negative EBITDA
Underperformed the market in the last 1 year
Stock DNA
Garments & Apparels
INR 25 Cr (Micro Cap)
NA (Loss Making)
34
0.00%
0.83
-26.36%
2.79
Total Returns (Price + Dividend) 
Skybiotech Healt for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Skybiotech Healthcare Q3 FY26: Mounting Losses Signal Deepening Operational Crisis
Skybiotech Healthcare Limited reported a net loss of ₹0.48 crores for Q3 FY26 (Oct-Dec'25), marking a sequential deterioration of 54.84% from Q2 FY26's loss of ₹0.31 crores. The micro-cap garments and apparels company, with a market capitalisation of just ₹27.00 crores, continues to struggle with operational inefficiencies as revenue collapsed 50.00% quarter-on-quarter to ₹0.96 crores. The stock traded at ₹144.90 on February 16, 2026, down 35.54% over the past year, reflecting persistent investor concerns about the company's viability.
Read full news articleAre Kapil Cotex Ltd latest results good or bad?
Kapil Cotex Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported a net loss of ₹0.31 crores, which marks a substantial deterioration compared to the previous quarter. Revenue for the quarter stood at ₹1.92 crores, reflecting a quarter-on-quarter decline of 19.67%, although it did show a year-on-year growth of 20.00% compared to the same quarter last year. This inconsistency in revenue generation highlights the company's struggle to maintain stable business momentum. The operating margin has shifted dramatically into negative territory at -11.46%, down from a positive margin of 3.35% in the prior quarter, indicating severe operational inefficiencies. The profit after tax (PAT) margin also fell to -16.15%, further emphasizing the company's profitability issues. The company has been facing difficulties in its core textile operations, leading to a pivot to...
Read full news article
Kapil Cotex Ltd is Rated Strong Sell
Kapil Cotex Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 December 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 12 February 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article Announcements 
Result- Financial Result For Quarter Ended On December 31St 2025
14-Feb-2026 | Source : BSESubmission of Un-Audited Financial Results for the Quarter ended on 31st December 2025
Board Meeting Outcome for Outcome Of Board Meeting To Considered And Approved Un-Audited Financials For The Quarter Ended On 31St December 2025
14-Feb-2026 | Source : BSEOutcome of Board Meeting to Considered and Approved Un-Audited Financials for the Quarter ended on 31st December 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On 31St December 2025
11-Feb-2026 | Source : BSESkybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve Approval of Unaudited Financial Results for the Quarter ended on 31st December 2025
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Prakashchandra Rathi (45.16%)
Ganesh Shivprasad Lahoti (4.44%)
34.88%
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is -61.90% vs 0.00% in Dec 2024
YoY Growth in quarter ended Dec 2025 is -23.08% vs -136.45% in Dec 2024
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is 100.00% vs 50.00% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -500.00% vs -100.95% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024
YoY Growth in year ended Mar 2025 is -96.10% vs 15,500.00% in Mar 2024






